艾司西酞普兰对冠心病患者心理症状及心血管结局的影响:随机对照试验的系统综述与荟萃分析。
完整摘要 · 中文译文
背景与目的:冠心病(CHD)患者常合并抑郁和焦虑,这会恶化预后。艾司西酞普兰是一种选择性5-羟色胺再摄取抑制剂,用于治疗这些症状,但其在冠心病患者中心理和心血管效应的证据有限。本系统综述和荟萃分析评估了其对冠心病患者心理症状和心血管结局的影响。 方法:我们系统检索了五个数据库中关于艾司西酞普兰与对照用于成人冠心病患者的随机对照试验(RCT)。提取数据以避免重复计数;延长随访数据单独分析。结局包括抑郁/焦虑量表变化、主要不良心血管事件(MACE)、全因死亡率、心肌梗死和血运重建。采用随机效应模型和敏感性分析。 结果:共纳入五项随机对照试验。总体抑郁评分变化不显著(SMD = -0.70,95% CI -1.57至0.18),但中期(12-24周)随访显示改善(SMD = -0.39,95% CI -0.58至-0.20)。艾司西酞普兰组焦虑评分显著降低(SMD = -0.64,95% CI -1.12至-0.17)。两项研究的汇总数据与主要不良心血管事件(RR = 0.74,95% CI 0.59至0.94)和心肌梗死(RR = 0.53,95% CI 0.29至0.96)的降低相符,然而,约90%的汇总权重来自单项试验的治疗后随访,因此这些发现属于假设生成性。全因死亡率未观察到统计学显著的组间差异 或血运重建。 结论:艾司西酞普兰对冠心病患者的部分心理症状似乎有效,且无证据表明存在重大心血管危害;当前证据不足以确立其心血管获益,观察到的MACE和心肌梗死减少具有假说生成性质。治疗应主要以改善心理状态和生活质量为目标。
完整摘要 · 英文原文
BACKGROUND AND OBJECTIVE: Patients with coronary heart disease (CHD) often have comorbid depression and anxiety, which worsen prognosis. Escitalopram, a selective serotonin reuptake inhibitor, is used for these symptoms, but evidence on its psychological and cardiovascular effects in CHD is limited. This systematic review and meta-analysis evaluated its effects on psychological symptoms and cardiovascular outcomes in CHD. METHODS: We systematically searched five databases for randomized controlled trials (RCTs) of escitalopram vs. control in adults with CHD. Data were extracted to avoid double counting; extended follow-up data were analyzed separately. Outcomes included depression/anxiety scale changes, major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction, and revascularization. Random-effects models and sensitivity analyses were used. RESULTS: Five RCTs were included. Overall depression score change was not significant (SMD = -0.70, 95% CI -1.57 to 0.18), but medium-term (12-24 weeks) follow-up showed improvement (SMD = -0.39, 95% CI -0.58 to -0.20). Anxiety scores significantly decreased with escitalopram (SMD = -0.64, 95% CI -1.12 to -0.17). Pooled data from two studies were compatible with reductions in MACE (RR = 0.74, 95% CI 0.59 to 0.94) and myocardial infarction (RR = 0.53, 95% CI 0.29 to 0.96), however, approximately 90% of the pooled weight came from the post-treatment follow-up of a single trial, so these findings are hypothesis-generating. No statistically significant between-group differences were observed for all-cause mortality or revascularization. CONCLUSION: Escitalopram appears effective for selected psychological symptoms in CHD without evidence of major cardiovascular harm; current evidence is insufficient to establish a cardiovascular benefit, and the observed MACE and myocardial infarction reductions are hypothesis-generating. Treatment should aim primarily to improve psychological well-being and quality of life.